Advertisement

Developmental Programming of Polycystic Ovary Syndrome: Role of Prenatal Androgen Excess

  • Agathocles Tsatsoulis
Chapter
Part of the Contemporary Diabetes book series (CDI)

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine/metabolic disorder in women, characterized by hyperandrogenism, chronic anovulation, and/or polycystic ovaries in association with android fat distribution and insulin resistance/hyperinsulinism. The etiology of PCOS remains elusive but there is increasing evidence that the phenotypic traits of the syndrome may be programmed in utero by androgen excess.

Thus, female primates, exposed to androgen excess during fetal life, exhibit the reproductive and metabolic features of PCOS in adulthood. Women with congenital 21-hydroxylase deficiency and congenital adrenal virilizing tumors develop features characteristic of PCOS during adult life, despite the normalization of androgen excess after birth. Rare cases of women with congenital sex hormone-binding globulin (SHBG) and P450 aromatase deficiency may also develop some of the features of PCOS in adulthood.

The potential sources of gestational hyperandrogenism to account for the developmental programming of PCOS in humans are not clearly understood. However, maternal and/or fetal hyperandrogenism, in association with reduced placental SHBG and/or aromatase activity, can provide a plausible mechanism and this, in part, may be genetically determined. Indeed, genetic association studies have indicated that common variants of genes determining androgen activity or genes that influence the availability of androgens to target tissues are associated with PCOS and increased androgen levels. These genetic variants may provide the genetic link to prenatal androgenization in human PCOS.

It appears, therefore, that prenatal androgenization of the female fetus, induced by genetic factors and environmental signals, or by the interaction of both, may program the differentiating target tissues toward the development of PCOS in adult life.

Key words

Polycystic ovary syndrome Hyperandrogenism Developmental programming Genetic polymorphisms Prenatal androgenization 

References

  1. 1.
    Barker DJP, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993;345:938–941Google Scholar
  2. 2.
    Barker DJP, Hales CN, Fall CH, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome x): relation to reduced fetal growth. Diabetologia 1993;36:62–67PubMedGoogle Scholar
  3. 3.
    Ibanez L, Potau N, Francois I, De Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558–3562PubMedGoogle Scholar
  4. 4.
    Gluckman PD, Hanson MA. The developmental origins of the metabolic syndrome. Trends Endocrinol Metab 2004;15:183–187PubMedGoogle Scholar
  5. 5.
    Lucas A. Programming by early nutrition in man. Ciba Found Symp 1991;156:38–50PubMedGoogle Scholar
  6. 6.
    Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences. Physiology 2005;21:29–37Google Scholar
  7. 7.
    Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol 2000;185:61–71Google Scholar
  8. 8.
    Arai Y, Gorski RA. Critical exposure time for androgenization of the developing hypothalamus in the female rat. Endocrinology 1968;82:1010–1014PubMedGoogle Scholar
  9. 9.
    Gustafsson J-A, Mode A, Norstedt G, Skett P. Sex steroid induced changes in hepatic enzymes. Annu Rev Physiol 1983;45:51–60PubMedGoogle Scholar
  10. 10.
    Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome – a hypothesis. J Endocrinol 2002;174:1–5PubMedGoogle Scholar
  11. 11.
    Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749PubMedGoogle Scholar
  12. 12.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–1236PubMedGoogle Scholar
  13. 13.
    Ehrmann DA, Liljenquist DR, Kasra K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53PubMedGoogle Scholar
  14. 14.
    Kravariti M, Naka KK, Kalantaridou SN et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088–5095PubMedGoogle Scholar
  15. 15.
    Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861PubMedGoogle Scholar
  16. 16.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25Google Scholar
  17. 17.
    Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a national approach. In: Dunaif A, Givens JR, Haseltine FP (eds). Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. Boston, MA: Blackwell, 1992, pp. 337–384Google Scholar
  18. 18.
    Azziz R, Carmina E, Dewailly B, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–4245.PubMedGoogle Scholar
  19. 19.
    Nelson VL, Legro RS, Strauss JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946–957PubMedGoogle Scholar
  20. 20.
    Wickenheisser JK, Nelson-De Grave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol Metab 2006;17:63–69Google Scholar
  21. 21.
    Wood JR, Nelson VL, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003;278:26380–26390PubMedGoogle Scholar
  22. 22.
    Wood JR, Ho CK, Nelson-De Grave VL, McAllister JM, Strauss JF III. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 2004;63:51–60PubMedGoogle Scholar
  23. 23.
    Jansen E, Laven JSE, Dommerhot HBR, et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol 2004;18:3050–3063PubMedGoogle Scholar
  24. 24.
    Xita N, Tsatsoulis A. Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006;91:1660–1666PubMedGoogle Scholar
  25. 25.
    Haque WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf) 1990;33:501–510Google Scholar
  26. 26.
    Barnes RB, Rosenfield RC, Ehrmann DA et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994;79:1328–1333PubMedGoogle Scholar
  27. 27.
    Miller WL. P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 2004;15:311–315PubMedGoogle Scholar
  28. 28.
    Morishima A, Grumbach MM, Simpson ER, Fisher C, Kenan Q. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689–3698PubMedGoogle Scholar
  29. 29.
    Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. Human sex-hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. J Clin Invest 2002;109:973–981PubMedGoogle Scholar
  30. 30.
    Abbott DH, Dumesic DA, Eisner JR, Kemnitz JW, Goy RW. The prenatally androgenized female rhesus monkey as a model for polycystic ovarian syndrome. In: Azziz R, Nestler JE, Dewailly D (eds). Androgen Excess Disorders in Women. Philadelphia, PA: Lippincott-Raven, 1997, pp. 369–382Google Scholar
  31. 31.
    Resko JA, Buhl AE, Phoenix CH. Treatment of pregnant rhesus macaques with testosterone propionate: observations on its fate in the fetus. Biol Reprod 1987;37:1185–1191PubMedGoogle Scholar
  32. 32.
    Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 2002;77:167–172PubMedGoogle Scholar
  33. 33.
    Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:6630–6637PubMedGoogle Scholar
  34. 34.
    Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab 1998;9:62–67PubMedGoogle Scholar
  35. 35.
    Padmanabhan V, Evans N, Taylor JA, Robinson JE. Prenatal exposure to androgens leads to the development of cystic ovaries in the sheep. Biol Reprod 1998;56(Suppl 1):194Google Scholar
  36. 36.
    Dumesic DA, Abbott DH, Eisner JR, Goy RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril 1997;67:155–163PubMedGoogle Scholar
  37. 37.
    Robinson JE, Forsdike RA, Taylor JA. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 1999;140:5797–5805PubMedGoogle Scholar
  38. 38.
    Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome. Hum Reprod Update 2005;11:357–374PubMedGoogle Scholar
  39. 39.
    Eisnher JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res 2003;11:279–286Google Scholar
  40. 40.
    Bruns CM, Baum ST, Colman RJ, et al. Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome (PCOS). Int J Obes 2007;31:1579–1585Google Scholar
  41. 41.
    Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000;85:1206–1210PubMedGoogle Scholar
  42. 42.
    Recabarren SE, Padmanabhan V, Codner E, et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol 2005;289:E801–E806Google Scholar
  43. 43.
    King AJ, Olivier NB, Mohankumar PS, Lee JS, Padmanabham V, Fink GD. Hypertension caused by prenatal testosterone excess in female sheep. Am J Physiol Endocrinol Metab, 2007;292:E1837–E1841PubMedGoogle Scholar
  44. 44.
    Bruns CM, Baum ST, Colman RJ, et al. Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J Clin Endocrinol Metab 2004;89:6218–6223PubMedGoogle Scholar
  45. 45.
    Ibanez L, Dimartino-Nardi J, Potan N, Saenger P. Premature adrenarche-normal variant or forerunner of adult disease? Endocr Rev 2000;21:671–696PubMedGoogle Scholar
  46. 46.
    Ibanez L, Potau N, deZegher FI. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558–3562PubMedGoogle Scholar
  47. 47.
    Charkaluk ML, Trivin C, Brauner R. Premature pubarche as an indicator of how body weight influences the onset of adrenarche. Eur J Pediatr 2004;163:89–93PubMedGoogle Scholar
  48. 48.
    Meas T, Chevenne D, Thibaud E, et al. Endocrine consequences of premature pubarche in postpubertal caucasian girls. Clin Endocrinol (Oxf) 2002;57:101–106Google Scholar
  49. 49.
    Ibanez L, Potau N, Marcos MV, de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 1999;84:4739–4741PubMedGoogle Scholar
  50. 50.
    Ghirri P, Bernardini M, Vuerich M, et al. Adrenarche, pubertal development, age at menarche and final height of full-term, born small for gestational age (SGA) girls. Gynecol Endocrinol 2001;15:91–97PubMedGoogle Scholar
  51. 51.
    Veening MA, van Weissenbruch MM, Roord JJ, de Delamarre-van Waal HA. Pubertal development in children born small for gestational age. J Pediatr Endocrinol Metab 2004;17:1497–1506PubMedGoogle Scholar
  52. 52.
    Ong KK, Potau N, Petry CJ, et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004;89:2647–2651PubMedGoogle Scholar
  53. 53.
    De Zegher F, Ibanez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 2006;86:S4-S5PubMedGoogle Scholar
  54. 54.
    Ibanez L, Jaramillo A, Enriquez G, et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod 2007;22:395–400PubMedGoogle Scholar
  55. 55.
    Barker DJ, Eriksson TG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int Epidemiol 2002;31:1235–1239Google Scholar
  56. 56.
    Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997;350:1131–1135PubMedGoogle Scholar
  57. 57.
    Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003;27:710–715PubMedGoogle Scholar
  58. 58.
    Michelmore K, Ong K, Mason S, et al. Clinical features of women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001;55:439–446Google Scholar
  59. 59.
    Benediktsson R, Calder AA, Edwards CR, Seckl JR. Placental 11β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997;46:161–166Google Scholar
  60. 60.
    Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002;17:2573–2579PubMedGoogle Scholar
  61. 61.
    Sir-Petermann T, Devoto L, Maliqueo M, Peirano P, Recabarren SE, Wildt L. Resumption of ovarian function during lactational amenorrhoea in breastfeeding women with polycystic ovarian syndrome: endocrine aspects. Hum Reprod 2001;16:1603–1610PubMedGoogle Scholar
  62. 62.
    Mason JI, Vshijima K, Doody KM, et al. Regulation of expression of the 3β-hydroxysteroid dehydrogenase of human placenta and fetal adrenal. J Steroid Biochem Mol Biol 1993;47:151–159PubMedGoogle Scholar
  63. 63.
    Nestler JE. Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor-1. Endocrinology 1987;121:1845–1852PubMedGoogle Scholar
  64. 64.
    Nestler JE. Insulin and insulin-like growth factor-1 stimulate the 3β-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology 1989;125:2127–2133PubMedGoogle Scholar
  65. 65.
    Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89PubMedGoogle Scholar
  66. 66.
    Sam S, Legro RS, Essah P, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006;103:7030–7035PubMedGoogle Scholar
  67. 67.
    Sir-Petermann T, Maliqueo M, Codner E et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:4637–4642PubMedGoogle Scholar
  68. 68.
    Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:3105–3109PubMedGoogle Scholar
  69. 69.
    Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005;20:2122–2126PubMedGoogle Scholar
  70. 70.
    Turhan NO, Seckin NC, Rybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynecol Obstet 2003;81:163–168Google Scholar
  71. 71.
    Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323–1330PubMedGoogle Scholar
  72. 72.
    Gartsen SM, Jacobsen G, Romundstad P. Maternal testosterone levels during pregnancy are associated with offspring size at birth. Eur J Endocrinol 2006;155:365–370Google Scholar
  73. 73.
    Steckler T, Wang T, Bartol FF, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 2005;146:3185–3193PubMedGoogle Scholar
  74. 74.
    Gitau R, Adams D, Fisk NM, Glover V. Fetal plasma testosterone correlates positively with cortisol. Arch Dis Child Fetal Neonatal Ed 2005;90:F166-F169PubMedGoogle Scholar
  75. 75.
    Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997;277:1669–1672PubMedGoogle Scholar
  76. 76.
    Zhou Y, Genbacer O, Damsky CH, Fisher SJ. Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and pre-eclampsia. J Reprod Immunol 1998;39:197–213PubMedGoogle Scholar
  77. 77.
    Zamudio S, Leslie KK, White M, Hagerman DD, Moore LG. Low serum estradiol and high serum progesterone concentrations characterize hypertensive pregnancies at high altitude. J Soc Gynecol Investig 1994;1:197–205PubMedGoogle Scholar
  78. 78.
    Jiang B, Kamat A, Mendelson CR. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (Mannalien Achaete-Scute Homologous Protein2). Mol Endocrinol 2000;14:1661–1673PubMedGoogle Scholar
  79. 79.
    Tchernof A, Toth MJ, Poehlanan ET. Sex hormone-binding globulin levels in middle-aged premenopausal women. Association with visceral obesity and metabolic profile. Diabetes Care 1999;22:1875–1881PubMedGoogle Scholar
  80. 80.
    Haffner SM, Katz MS, Stern MP, Dunn JF. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988;67:460–464Google Scholar
  81. 81.
    Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1998;67:460–464Google Scholar
  82. 82.
    Selvo DM, Hogerveen KN, Innis SM, Hammond GL. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 2007;117:3979–3987Google Scholar
  83. 83.
    Dickenson SM, Gore AC. Estrogenic environmental endocrine-disrupting chemical effects on reproductive neuroendocrine function and dysfunction across the life cycle. Rev Endocr Metab Disord 2007;8:143–159Google Scholar
  84. 84.
    Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc Soc Exp Biol Med 2000;224:61–68PubMedGoogle Scholar
  85. 85.
    Haney AF, Newbold RR, McLachlan JA. Prenatal diethylstilbestrol exposure in the mouse: effects on ovarian histology and steroidogenesis in vitro. Biol Reprod 1984;30:471–478PubMedGoogle Scholar
  86. 86.
    Wu CH, Mangan CE, Burtnett MM, Michail G. Plasma hormones in DES-exposed females. Obstet Gynecol 1980;55:157–162PubMedGoogle Scholar
  87. 87.
    Bibbo M, Gill WB, Azizi F, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol 1977;49:1–8PubMedGoogle Scholar
  88. 88.
    Newbold RR, Padilla-Banks E, Snydrer RJ, Jefferson WN. Perinatal exposure to environmental estrogens and the development of obesity. Mol Nutr Food Res 2007;51:912–917PubMedGoogle Scholar
  89. 89.
    Matthiessen P, Gibbs P. Critical appraisal of the evidence for tributyltin-mediated endocrine disruption in mollusks. Environ Toxicol Chem 1998;17:37–43Google Scholar
  90. 90.
    Ogata R, Omara M, Shimasaki Y, et al. Two-generation reproductive toxicity study of tributyltin chloride in female rats. J Toxicol Environ Health 2001;63:127–144Google Scholar
  91. 91.
    Cooke GM. Effect of organotins on human aromatase activity in vitro. Toxicol Lett 2002;126:121–130PubMedGoogle Scholar
  92. 92.
    Mu YM, Yanase T, Nishi Y, Takayanagi R, Goto K, Nawata H. Combined treatment with specific ligands for PPARγ: RXR nuclear receptor system markedly inhibits the expression of cytochrome P450 arom in human granulosa cancer cells. Mol Cell Endocrinol 2001;181:239–248PubMedGoogle Scholar
  93. 93.
    Grun F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 2006;20:2141–2155PubMedGoogle Scholar
  94. 94.
    Grun F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signalling. Endocrinology 2006;147:550–555Google Scholar
  95. 95.
    Berube D, Sevalini GE, Gagne R, Hammond GL. Localization of human sex hormone-binding gene (SHBG) to the short arm of chromosome 17(17p12-p13). Cytogenet Cell Genet 1990;54:65–67PubMedGoogle Scholar
  96. 96.
    Toscano V, Balducci R, Bianchi P, Guglielmi R, Mangiantini A, Sciara F. Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation. J Steroid Biochem Mol Biol 1992;43:431–437PubMedGoogle Scholar
  97. 97.
    Ahrentsen OD, Jensen HK, Johnsen SG. Sex hormone-binding globulin deficiency 1982;2:377–378Google Scholar
  98. 98.
    Hogeveen KN, Talikka M, Hammond GL. Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem 2001;276:36383–36390PubMedGoogle Scholar
  99. 99.
    Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG)gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003;88:5976–5980PubMedGoogle Scholar
  100. 100.
    Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D 327 N polymorphism on serum sex hormone-binding globulin concentrations in hirsuit women. J Clin Endocrinol Metab 2004;89:917–924PubMedGoogle Scholar
  101. 101.
    Polonca F, Teran N, Gersak K. The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod 2007;22:1031–1036Google Scholar
  102. 102.
    Bulun SE. Aromatase deficiency in women and men: would you have predicted the phenotype? J Clin Endocrinol Metab 1996;81:867–871PubMedGoogle Scholar
  103. 103.
    Urbanek M, Legro RS, Driscoll DA et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;69:8573–8578Google Scholar
  104. 104.
    Söderlund D, Canto P, Carranza-Lira S, Méndez JP. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod 2005;20:965–969PubMedGoogle Scholar
  105. 105.
    Gharani N, Waterworth BW, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397–402PubMedGoogle Scholar
  106. 106.
    Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837–1843PubMedGoogle Scholar
  107. 107.
    Baghaei F, Rosmond R, Westberg L, et al. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res 2003;11:578–585PubMedGoogle Scholar
  108. 108.
    Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype. Eur J Endocrinol 2008;158:861–865PubMedGoogle Scholar
  109. 109.
    Gaasenbeek M, Powell BL, Sovio U et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 2004;89:2403–2413Google Scholar
  110. 110.
    Kimura S, Matsumoto T, Matsuyama K et al. Androgen receptor function in folliculogenesis and its clinical implication in premature ovarian failure. Trends Endocrinol Metab 2007;18:181–189Google Scholar
  111. 111.
    Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181–3186PubMedGoogle Scholar
  112. 112.
    Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor β gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001;86:2562–2568PubMedGoogle Scholar
  113. 113.
    Ibanez L, Ong KK, Mongan N, et al. Androgen receptor gene CAG repeat polymorphism in development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:3333–3338PubMedGoogle Scholar
  114. 114.
    Legro RS, Shahbahrami B, Lobo PA, Kovacs BW. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994;83:701–706PubMedGoogle Scholar
  115. 115.
    Misfud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85:3484–3488Google Scholar
  116. 116.
    Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161–165PubMedGoogle Scholar
  117. 117.
    Calvo RM, Asuncion M, Saucho J, San Millan JL, Escobar-Morreale HF. The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation in the pathogenesis of hirsutism. J Clin Endocrinol Metab 2000;85:1735–1740PubMedGoogle Scholar
  118. 118.
    Jaaskelainen J, Korhonen S, Voutilainen R, Hippelainen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 2005;83:1724–1728PubMedGoogle Scholar
  119. 119.
    Edwarls A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variations at five trimenic and tetramenic tandem repeat loci in four human population groups. Genomics 1992; 241–253Google Scholar
  120. 120.
    Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The role of sex hormone-binding globulin and androgen reception gene variants in the development of polycystic ovary syndrome. Hum Reprod 2008;23:693–698PubMedGoogle Scholar
  121. 121.
    Britt KL, Findlay JK. Estrogen actions in the ovary revisited. J Endocrinol 2002; 175:269–276PubMedGoogle Scholar
  122. 122.
    Robinson J. Prenatal programming at the female reproductive neuroendocrine system by androgens. Reproduction 2006; 132:539–547PubMedGoogle Scholar
  123. 123.
    Escobar-Morreale HF, Sam Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266–272PubMedGoogle Scholar
  124. 124.
    Auger AP, Hexter DP, McCarthy MM. Sex differences in the phosphorylations of cAMP response element binding protein (CREB) in neonatal fat brain. Brain Res 2001; 890:110–117PubMedGoogle Scholar
  125. 125.
    Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic disease. Nutrition 2004; 20:63–68Google Scholar
  126. 126.
    Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses 2008; 70:638–642PubMedGoogle Scholar
  127. 127.
    Lavoie HA. Epigenetic control of ovarian function: the emerging role of histone modification. Mol Cell Endocrinol 2005; 243:12–18PubMedGoogle Scholar
  128. 128.
    Drake AJ, Walker BR. The intergenerational effects of fetal programming: non-genomic mechanisms for the inheritance of low birth weight and cardiovascular risk. J Endocrinol 2004; 180:1–16PubMedGoogle Scholar
  129. 129.
    Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26:251–282PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Agathocles Tsatsoulis
    • 1
  1. 1.Dept. of EndocrinologyUniversity of Ioannina Medical SchoolIoanninaGreece

Personalised recommendations